Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports PR Newswire NEW YORK, March 25, 2015 NEW YORK, March 25, 2015 /PRNewswire/...
Burton, MI - October 02, 2014 - InvestorsHub NewsWire - Anavex Life Sciences Corp. (OTCQB: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of novel drug...
OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX® PR Newswire NEW YORK, July 11, 2014 NEW YORK, July 11, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open...
VANCOUVER,B.C., May 5, 2014 (GLOBE NEWSWIRE) -- A hundred and fifty years ago, Harry Barr's (President and CEO of Next Gen Metals) (CSE:N) (OTC Pink:NXTTF), ancestors began farming in the Ottawa...
Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project Sponsorship will fund completion of monograph to guide commercial production in Canada PR...
Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance PR Newswire VANCOUVER, British Columbia, March 8, 2013 VANCOUVER...
Abattis Signs LOI With Crudessence Kombucha Inc. To License Infused, Blended Kombucha Tea PR Newswire VANCOUVER, British Columbia, March 6, 2013 VANCOUVER, British Columbia, March 6, 2013...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 4800 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 21980 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 44438 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 34812 | 1.14E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 24772 | 1.16E-6 | CS |
| 156 | 0 | 0 | 1.0E-6 | 0.001 | 1.0E-6 | 20680 | 1.97E-6 | CS |
| 260 | -0.015499 | -99.9935483871 | 0.0155 | 0.077 | 1.0E-6 | 305094 | 0.01393225 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
